Advances in Chronic Kidney Disease
Volume 17, Issue 4 , Pages 320-328, July 2010

Medication Issues in Older Individuals With CKD

  • Dena E. Rifkin

      Affiliations

    • Divisions of Nephrology and Family and Preventive Medicine, Veterans' Affairs Medical Center, San Diego, and the University of California, San Diego, CA
    • ,
  • Wolfgang C. Winkelmayer

      Affiliations

    • Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA
    • Corresponding Author InformationAddress correspondence to Wolfgang C. Winkelmayer, MD, ScD, Division of Nephrology, Stanford University School of Medicine, 780 Welch Rd, Ste 106, Palo Alto, CA 94304.

Older US adults bear a substantial burden of chronic disease and take an average of five prescription and non-prescription medications per day. Recent data suggest that over 20% of older adults have chronic kidney disease (CKD) as defined by an impaired glomerular filtration rate. These individuals often have multiple comorbidities, including diabetes, hypertension, and cardiovascular disease. Although patients with CKD may receive substantial benefits from prescribed medications, they are also at high risk for adverse drug events and polypharmacy. In this review, we outline the risks and benefits of medication use in the CKD population as a specific case within geriatric pharmacoepidemiology as a framework.

Key Words: Prescription drugs, Geriatrics, Utilization, Effectiveness, Safety, Drug interaction, Pharmacoepidemiology

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Rifkin has nothing to disclose; Dr. Winkelmayer's recent support includes a Scientist Development Grant from the American Heart Association, a Norman S. Coplon Extramural Research Program Award from Satellite Healthcare, Inc., support from the National Institutes of Health, and investigator-initiated grants from Amgen and GlaxoSmithKline. In the last 3 years, he has participated in advisory boards or been a consultant to AMAG Pharmaceuticals, Amgen, Fibrogen, and Fresenius, MD, MPH, ScD, FASN.

PII: S1548-5595(10)00048-0

doi:10.1053/j.ackd.2010.03.005

Advances in Chronic Kidney Disease
Volume 17, Issue 4 , Pages 320-328, July 2010

Article Tools